дифдиагностика лейкоза

Middle age of patients has made 64 years; 84 % had positive рецепторный the status, 34 % - positive axillary лимфоузлы, 21 % of patients received адъювантную chemotherapy earlier. Reception анастрозола associated with reduction of risk рецидивирования on 17 % (1 % in absolute values) in comparison with тамоксифеном (р=0,0129); the combination анастрозола and тамоксифена did not differ on efficiency from monotherapy тамоксифеном. It is necessary to note, that reception анастрозола associated also with essential decrease{reduction} in risk of development контралатерального a cancer dairy железы (р=0,0068). Костно-muscular pains, and also crises of bones much more often were observed in group анастрозола while тромбоэмболические episodes and gynecologic complications, including a cancer эндометрия, much more often met in group тамоксифена. Thus, анастрозол it can be considered{examined} as alternative тамоксифену at patients in менопаузе with positive receptors. Reception анастрозола has considerably lowered frequency of development контралатерального a cancer, and this fact is the basis for studying group ингибиторов ароматазы as means of preventive maintenance of a cancer dairy железы in groups with the raised{increased} risk. Подробнее...

In research AGO-GINECO authors have estimated expediency of addition антрациклинов to a combination карбоплатин паклитаксел. Inclusion эпирубицина has strengthened toxicity of a combination, but has not improved results of therapy [10]. In research SCOTROC comparison available today in our disposal таксанов is made: паклитаксела and доцетаксела [11]. Both preparations in a combination with карбоплатином have shown identical frequency of objective effects and time before progressing. The combination карбоплатин-паклитаксел possessed more expressed нейротоксичностью while карбоплатин-доцетаксел caused development нейтропении is more often. Подробнее...